{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T05:37:00Z","timestamp":1794461820278,"version":"4.9.1"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:sec id=\"ab-hoi250027-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Lipoprotein(a) [Lp(a)] is independently associated with atherosclerotic cardiovascular disease (ASCVD) risk but is not included in the new American Heart Association Predicting Risk of Cardiovascular Disease Events (PREVENT) equations for CVD risk assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi250027-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the performance of these equations in individuals with elevated Lp(a).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi250027-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>Cohort study involving 314\u202f783 participants from the multicenter Multi-Ethnic Study of Atherosclerosis (MESA, 2000-2018; n\u2009=\u20096670) and the population-based UK Biobank (UKB, 2006-2022; n\u2009=\u2009308\u202f113) without known cardiovascular disease with available Lp(a) measurements. Analyses were conducted March 25, 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi250027-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Elevated Lp(a) level of 125 nmol\/L or higher.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi250027-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Coronary heart disease (CHD), ASCVD, heart failure (HF), and total CVD. Participants were categorized as low (&amp;amp;lt;5%), borderline (5% to &amp;amp;lt;7.5%) intermediate (7.5% to &amp;amp;lt;20%), and high (\u226520%) risk of each outcome. Ten-year observed event rates were calculated, and the association between elevated Lp(a) and outcomes overall and by risk category was evaluated in age- and sex-adjusted Cox proportional hazards models. Improvement in risk prediction with the addition of elevated Lp(a) was evaluated using continuous and categorical net reclassification improvement (NRI) (using the above cut points).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi250027-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 314\u202f783 participants (mean [SD] age, 62.1 [10.2] years and 3523 females [53%] in MESA; mean [SD] age, 56.3 [8.1] years; 169\u202f648 females [55%] in the UKB), observed 10-year ASCVD event rates generally fell within the bounds of predicted risk categories regardless of Lp(a) level, although participants with elevated Lp(a) had higher event rates than did those with nonelevated Lp(a) (hazard ratio [HR], 1.30; 95% CI, 1.22-1.38) with similar results for CHD, HF, and total CVD. For CHD, the strongest association was among low-risk individuals (\n                      <jats:italic>P<\/jats:italic>\n                      for interaction\u2009=\u2009.31). The addition of elevated Lp(a) values to PREVENT modestly improved ASCVD risk prediction (category-free NRI, 0.058; 95% CI, 0.043-0.065; categorical NRI, 0.006, 95% CI, 0.004-0.011) with the greatest improvement in borderline-risk; when Lp(a) was evaluated continuously, the greatest improvement in prediction was among individuals at low risk. For CHD, the greatest improvement in prediction was in low- and high-risk individuals.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi250027-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this analysis of 2 cohort studies, the novel PREVENT equations performed well for risk prediction overall, including among individuals with elevated Lp(a). However, Lp(a) values remain independently associated with higher risk, and Lp(a) may improve personalized risk assessment, particularly among specific subgroups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2025.1603","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T11:00:28Z","timestamp":1749034828000},"page":"810","source":"Crossref","is-referenced-by-count":45,"title":["<b>AHA PREVENT Equations and Lipoprotein(a) for Cardiovascular Disease Risk<\/b>"],"prefix":"10.1001","volume":"10","author":[{"given":"Harpreet S.","family":"Bhatia","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ambrosio","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Virginia Commonwealth University, Richmond"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Razavi","sequence":"additional","affiliation":[{"name":"Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela L.","family":"Alebna","sequence":"additional","affiliation":[{"name":"Pauley Heart Center, Virginia Commonwealth University, Richmond"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Yeang","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared A.","family":"Spitz","sequence":"additional","affiliation":[{"name":"Inova Schar Heart and Vascular, Fairfax, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaideep","family":"Patel","sequence":"additional","affiliation":[{"name":"Ciccarone Center for the Prevention of Atherosclerotic Cardiovascular Disease, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Y.","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Sperling","sequence":"additional","affiliation":[{"name":"Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Section on Cardiovascular Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, University of California, San Diego, La Jolla"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Mehta","sequence":"additional","affiliation":[{"name":"Pauley Heart Center, Virginia Commonwealth University, Richmond"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"hoi250027r1","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies.","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"10459","key":"hoi250027r2","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease.","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"hoi250027r3","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines.","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi250027r4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"8","key":"hoi250027r5","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults.","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"issue":"3","key":"hoi250027r6","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice.","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"24","key":"hoi250027r7","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines.","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"hoi250027r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.117217","article-title":"Lipoprotein(a) and the pooled cohort equations for ASCVD risk prediction: the Multi-Ethnic Study of Atherosclerosis.","volume":"381","author":"Bhatia","year":"2023","journal-title":"Atherosclerosis"},{"issue":"6","key":"hoi250027r9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations.","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"issue":"9","key":"hoi250027r10","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/aje\/kwf113","article-title":"Multi-Ethnic Study of Atherosclerosis: objectives and design.","volume":"156","author":"Bild","year":"2002","journal-title":"Am J Epidemiol"},{"issue":"6","key":"hoi250027r11","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association\u2019s PREVENT Equations.","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"issue":"2","key":"hoi250027r12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI Working group recommendations to reduce lipoprotein(a)\u2013mediated risk of cardiovascular disease and aortic stenosis.","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"hoi250027r13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jama.2024.13887","article-title":"Statins for Primary prevention of cardiovascular disease\u2014with PREVENT, what\u2019s a clinician to do?","volume":"332","author":"Khan","year":"2024","journal-title":"JAMA"},{"issue":"12","key":"hoi250027r14","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jacc.2010.04.048","article-title":"Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events.","volume":"56","author":"Tsimikas","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"hoi250027r15","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction.","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"hoi250027r16","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck study.","volume":"64","author":"Willeit","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"hoi250027r17","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.jacc.2017.01.017","article-title":"Lipoprotein(a) improves cardiovascular risk prediction based on established risk algorithms.","volume":"69","author":"Verbeek","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"hoi250027r18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2018.12.022","article-title":"Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: the Atherosclerosis Risk in Communities study.","volume":"282","author":"Saeed","year":"2019","journal-title":"Atherosclerosis"},{"issue":"13","key":"hoi250027r19","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1161\/CIRCULATIONAHA.117.031855","article-title":"Quantifying importance of major risk factors for coronary heart disease.","volume":"139","author":"Pencina","year":"2019","journal-title":"Circulation"},{"key":"hoi250027r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100661","article-title":"Polygenic risk and incident coronary heart disease in a large multiethnic cohort.","volume":"18","author":"Iribarren","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"3","key":"hoi250027r21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1161\/CIRCULATIONAHA.116.024611","article-title":"LPA gene, ethnicity, and cardiovascular events.","volume":"135","author":"Lee","year":"2017","journal-title":"Circulation"},{"issue":"6","key":"hoi250027r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.100939","article-title":"E pluribus unum.","volume":"3","author":"Patel","year":"2024","journal-title":"JACC Adv"},{"issue":"18","key":"hoi250027r23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.031255","article-title":"Lipoprotein(a) testing trends in a large academic health system in the United States.","volume":"12","author":"Bhatia","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"hoi250027r24","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/CIR.0000000000000678","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines.","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"hoi250027r25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/MOL.0000000000000950","article-title":"Strategies for management of patients with elevated lipoprotein(a).","volume":"35","author":"Ellberg","year":"2024","journal-title":"Curr Opin Lipidol"},{"issue":"8","key":"hoi250027r26","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1001\/jamainternmed.2024.1302","article-title":"Atherosclerotic cardiovascular disease risk estimates using the Predicting Risk of Cardiovascular Disease Events equations.","volume":"184","author":"Anderson","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"39","key":"hoi250027r27","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"hoi250027r28","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size.","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J Clin Lipidol"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2835022\/jamacardiology_bhatia_2025_oi_250027_1754420629.7163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T15:00:55Z","timestamp":1755097255000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2835022"}},"subtitle":["Insights From MESA and the UK Biobank"],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2025.1603","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}